Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Allogeneic Cord Blood Regulatory T Cells Can Prevent Graft Vs. Host Disease and Preserve Graft Vs Leukemia Effect: Update on Phase I/II Clinical Trial

Ke Zeng, MD PhD, Hongbing Ma, MD PhD, Uday Popat, MD, Yago Nieto, MD PhD, Stefan O. Ciurea, MD, Amanda L. Olson, MD, Mi-Ae Lyu, PhD, Meixian Huang, Mitsutaka Nishimoto, MD PhD, Muzaffar H. Qazilbash, MD, Jennifer D Ramos, RN, Elizabeth J. Shpall, MD, Richard E. Champlin, MD, Simrit Parmar, MBBS, Borje S Andersson, MD PhD

Blood (2019) 134 (Supplement_1): 4547.

https://doi.org/10.1182/blood-2019-127726

Published: 2019

Journal Articles

Distinct Evolutionary Patterns in Chronic Lymphocytic Leukemia (CLL) during Resistance to Graft-Versus-Leukemia (GvL)

Blood (2019) 134 (Supplement_1): 516.

https://doi.org/10.1182/blood-2019-129520

Published: 2019

Journal Articles

Clonal and Single Cell Dynamics of Resistance to Graft-Versus-Leukemia (GvL) in Chronic Lymphocytic Leukemia (CLL)

Pavan Bachireddy, MD, Nikolaos Barkas, PhD, Sachet A Shukla, PhD, Samuel Freeman, Liudmila Elagina, PhD, Vinhkhang N Nguyen, Kendell Clement, PhD, Ignaty Leshchiner, PhD, Jennifer R. Brown, MD PhD, Donna S Neuberg, ScD, Vincent T. Ho, MD, Robert J. Soiffer, MD, Jerome Ritz, MD PhD, Gad Getz, PhD, Edwin P. Alyea, III, MD, Peter Kharchenko, PhD, Catherine J. Wu, MD

Blood (2018) 132 (Supplement 1): 820.

https://doi.org/10.1182/blood-2018-99-116681

Published: 2018

Journal Articles

Graft-Vs-Leukemia Effect in Acute Lymphoblastic Leukemia: Mild Acute Graft-Vs-Host Disease Protects Against Relapse and Improves Survival after Allogeneic Transplantation: A CIBMTR Analysis

Moshe Yeshurun, Daniel J. Weisdorf, MD, Mei-Jie Zhang, PhD, Hai-Lin Wang, MPH, Mary E. Flowers, MD, Marcos De Lima, MD, Jacob M. Rowe, MD, Brenda M. Sandmaier, MD, Martin S. Tallman, MD, Michael R Verneris, MD, Veronika Bachanova, MD PhD

Blood (2017) 130 (Supplement 1): 518.

https://doi.org/10.1182/blood.V130.Suppl_1.518.518

Published: 2017

Journal Articles

Clonal Evolution of Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation

Matt Christopher, MD PhD, Allegra A. Petti, PhD, Christopher Miller, PhD, Lukas D. Wartman, MD, Jacqueline E. Payton, MD PhD, Sharon Heath, Robert Fulton, John S. Welch, MD PhD, Matthew J. Walter, MD, Peter Westervelt, MD PhD, Daniel C. Link, MD, Richard K Wilson, PhD, Timothy J. Ley, MD, John F. DiPersio, MD, PhD

Blood (2016) 128 (22): 1528.

https://doi.org/10.1182/blood.V128.22.1528.1528

Published: 2016

Journal Articles

TCR Diversity Is a Predictive Marker for Donor Lymphocyte Infusion Response

Christian Schultze-Florey, MD, Solaiman Raha, Sarina Ravens, PhD, Leonie Kuhlmann, Melanie Drenker, Linda Oberdörfer, Anke Breithaupt, Elke Dammann, Lothar Hambach, MD, Michael Stadler, MD, Michael Heuser, MD, Felicitas Thol, MD, Reinhold Foerster, Prof., Arnold Ganser, MD, Immo Prinz, Prof., Christian Koenecke, MD

Blood (2016) 128 (22): 4605.

https://doi.org/10.1182/blood.V128.22.4605.4605

Published: 2016

Journal Articles

Mechanism and Activity of ILC2 Cells Post Allo-BMT

Danny W Bruce, PhD, Heather E Stefanski, MD PhD, Benjamin G. Vincent, MD, Trisha Dant, BS, Shannon Reisdorf, BS, Hemamalini Bommiasamy, PhD, David Serody, Justin E Wilson, PhD, Karen McKinnon, PhD, Warren D Shlomchik, MD, Paul M. Armistead, MD PhD, Jenny PY Ting, PhD, John T Woosley, MD PhD, Dietmar MW Zaiss, PhD, Bruce R. Blazar, MD, Andrew NJ McKenzie, PhD, James Coghill, MD, Jonathan S. Serody, MD

Blood (2016) 128 (22): 1155.

https://doi.org/10.1182/blood.V128.22.1155.1155

Published: 2016

Journal Articles

DONOR LYMPHOCYTE INFUSIONS (DLI): Risk Factors for Non Relapse Mortality (NRM) In 287 Patients Receiving DLI

Andrea Bacigalupo, MD, Anna Maria Raiola, Alida Dominietto, Carmen Di Grazia, Francesca Gualandi, Teresa Lamparelli, Stefania Bregante, Francesco Frassoni, MD, Riccardo Varaldo, Silvana Annunziata, Maria Teresa van Lint

Blood (2010) 116 (21): 2333.

https://doi.org/10.1182/blood.V116.21.2333.2333

Published: 2010

Journal Articles

GRAFT-VS-LEUKEMIA EFFECT in a MOUSE MODEL of CHRONIC MYELOID LEUKEMIA.

María L Lamana, Alberto Oviedo, Rosa Yañez, Montserrat Aldea, Antonio Rubio, Juan A. Bueren

Blood (2009) 114 (22): 4500.

https://doi.org/10.1182/blood.V114.22.4500.4500

Published: 2009

Journal Articles

Graft-Vs-Leukemia Effects of Allogeneic Stem Cell Transplantation from HLA-Haploidentical Family Members as Compared to HLA-Identical Sibling Donors

Hans Jochem Kolb, MD, Iris Bigalke, Dominik Termeer, Susanne Fritsch, Wolfgang Hill, Belinda Simoes, Andreas Hausmann, Christine Falk, Raymund Buhmann, Johanna Tischer, Georg Ledderose

Blood (2008) 112 (11): 3009.

https://doi.org/10.1182/blood.V112.11.3009.3009

Published: 2008

Journal Articles

Prospective Phase II Study of Biologic Assignment One Vs Two Unit Umbilical Cord Blood Transplant (UCBT) in the Reduced-Intensity Conditioning Setting.

Tamila L. Kindwall-Keller, DO, Yael Hegerfeldt, MD, Pingfu Fu, PhD, Hillard M. Lazarus, MD, Brenda W. Cooper, MD, Paul Barr, MD, Stanton L. Gerson, MD, Howard Meyerson, MD, Sally Erinc, RN, Richard J. Creger, PharmD, Laura Fanning, PhD, Nicholas Greco, PhD, Peter Haviernik, PhD, Mathew Lesniewski, PhD, Mary J. Laughlin, MD

Blood (2008) 112 (11): 1960.

https://doi.org/10.1182/blood.V112.11.1960.1960

Published: 2008

Journal Articles

Emergence of Dominant T-Cell Populations in Patients with CLL after Allogeneic Transplantation: Mediators for Gvl Effects?

Matthias Ritgen, MD, Monika Brueggemann, MD, PhD, Sebastian Boettcher, MD, Thorsten Raff, MD, Christiane Pott, MD, Michael Hallek, M.D., Michael Kneba, MD, PhD, Peter Dreger, MD

Blood (2008) 112 (11): 3503.

https://doi.org/10.1182/blood.V112.11.3503.3503

Published: 2008

Journal Articles

NM23-H2 Is a Tumor Associated Antigen (TAA) in Chronic Myeloid Leukemia (CML).

Sabine Tschiedel, Annette Jilo, Dietger W. Niederwieser

Blood (2007) 110 (11): 2932.

https://doi.org/10.1182/blood.V110.11.2932.2932

Published: 2007

Journal Articles

Donor-Derived T Cells Can Be Rendered Hyporesponsive to Alloantigen without Loss of Pathogen or Tumor Immune Responses.

Jeff Davies, Dongin Yuk, Lee Nadler, Eva Guinan

Blood (2007) 110 (11): 771.

https://doi.org/10.1182/blood.V110.11.771.771

Published: 2007

Journal Articles

A Distinct Pattern of Non-HLA Polymorphisms Predicts an Increased Risk for GvHD without Benefit of GvL in HLA Matched Sibling Transplants for Chronic Myeloid Leukemia (CML).

Blood (2006) 108 (11): 54.

https://doi.org/10.1182/blood.V108.11.54.54

Published: 2006

Journal Articles

Development of Improved Lentiviral ‘Suicide’ Gene Therapy for the Management of GvHD and GvL/GvT Responses in Allogeneic BMT.

Anton Neschadim, MSc, Takeya Sato, PhD, Daniel H. Fowler, MD, Arnon Lavie, PhD, Jeffrey A. Medin, PhD

Blood (2006) 108 (11): 3256.

https://doi.org/10.1182/blood.V108.11.3256.3256

Published: 2006

Journal Articles

Impaired GvL Potential of Natural Killer Cells Early Reconstituting Following Haploidentical HSCT.

Luca Vago, MD, Elisabetta Zino, BS, Simona Di Terlizzi, BS, Barbara Forno, MS, Maria T. Lupo Stanghellini, MD, Serena K. Perna, MD, Benedetta Mazzi, BS, Jacopo Peccatori, MD, Silvano Rossini, MD, Maria G. Roncarolo, MD, Chiara Bonini, MD, Fabio Ciceri, MD, Claudio Bordignon, MD, Katharina Fleischhauer, MD

Blood (2006) 108 (11): 3223.

https://doi.org/10.1182/blood.V108.11.3223.3223

Published: 2006

Journal Articles

N-Acetylcysteine Mildly Inhibits the Graft vs Leukemia Effect but Not the Lymphokine Activated Cells (LAK) Activity.

Michael Y. Shapira, MD, Lola Weiss, PhD, Shoshana Reich, Michael Zeira, PhD, Shimon Slavin, MD

Blood (2006) 108 (11): 5171.

https://doi.org/10.1182/blood.V108.11.5171.5171

Published: 2006

Journal Articles

Rejection of Primary Lymphoma Cells Derived from c-myc-Transgenic Mice after Haploidentical Transplantation: Treatment of the Tumor May Confer to Resistance Against GvL-Effect.

Madhusudhanan Sukumar, Andrea Wilke, Josef Mautner, PhD, Hans-Jochem Kolb, MD, PhD, Georg Bornkamm, MD, PhD, Armin Gerbitz, MD

Blood (2005) 106 (11): 5243.

https://doi.org/10.1182/blood.V106.11.5243.5243

Published: 2005

Journal Articles

Daily Monitoring of Cyclosporine (Csa) Allows Better Control of Graft vs. Leukaemia Effect (GvL): Single Centre Experience.

Mayukh Das, MBBS, DTM, Venkatasreekanth Sampath, MRCP, Margareta Angelica, RGN, Angela Leather, RGN, Mike Dennis, MRCP, MRCPATH, Jim Cavet, MRCP, MRCPATH, PhD, Effie Liakopoulou, MRCP, MRCPATH, PhD

Blood (2005) 106 (11): 5319.

https://doi.org/10.1182/blood.V106.11.5319.5319

Published: 2005

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Allogeneic Cord Blood Regulatory T Cells Can Prevent Graft Vs. Host Disease and Preserve Graft Vs Leukemia Effect: Update on Phase I/II Clinical Trial

Distinct Evolutionary Patterns in Chronic Lymphocytic Leukemia (CLL) during Resistance to Graft-Versus-Leukemia (GvL)

Clonal and Single Cell Dynamics of Resistance to Graft-Versus-Leukemia (GvL) in Chronic Lymphocytic Leukemia (CLL)

Graft-Vs-Leukemia Effect in Acute Lymphoblastic Leukemia: Mild Acute Graft-Vs-Host Disease Protects Against Relapse and Improves Survival after Allogeneic Transplantation: A CIBMTR Analysis

Clonal Evolution of Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation

TCR Diversity Is a Predictive Marker for Donor Lymphocyte Infusion Response

Mechanism and Activity of ILC2 Cells Post Allo-BMT

DONOR LYMPHOCYTE INFUSIONS (DLI): Risk Factors for Non Relapse Mortality (NRM) In 287 Patients Receiving DLI

GRAFT-VS-LEUKEMIA EFFECT in a MOUSE MODEL of CHRONIC MYELOID LEUKEMIA.

Graft-Vs-Leukemia Effects of Allogeneic Stem Cell Transplantation from HLA-Haploidentical Family Members as Compared to HLA-Identical Sibling Donors

Prospective Phase II Study of Biologic Assignment One Vs Two Unit Umbilical Cord Blood Transplant (UCBT) in the Reduced-Intensity Conditioning Setting.

Emergence of Dominant T-Cell Populations in Patients with CLL after Allogeneic Transplantation: Mediators for Gvl Effects?

NM23-H2 Is a Tumor Associated Antigen (TAA) in Chronic Myeloid Leukemia (CML).

Donor-Derived T Cells Can Be Rendered Hyporesponsive to Alloantigen without Loss of Pathogen or Tumor Immune Responses.

A Distinct Pattern of Non-HLA Polymorphisms Predicts an Increased Risk for GvHD without Benefit of GvL in HLA Matched Sibling Transplants for Chronic Myeloid Leukemia (CML).

Development of Improved Lentiviral ‘Suicide’ Gene Therapy for the Management of GvHD and GvL/GvT Responses in Allogeneic BMT.

Impaired GvL Potential of Natural Killer Cells Early Reconstituting Following Haploidentical HSCT.

N-Acetylcysteine Mildly Inhibits the Graft vs Leukemia Effect but Not the Lymphokine Activated Cells (LAK) Activity.

Rejection of Primary Lymphoma Cells Derived from c-myc-Transgenic Mice after Haploidentical Transplantation: Treatment of the Tumor May Confer to Resistance Against GvL-Effect.

Daily Monitoring of Cyclosporine (Csa) Allows Better Control of Graft vs. Leukaemia Effect (GvL): Single Centre Experience.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only